Brief: Vera Therapeutics Says ORIGIN Phase 2b Trial Met Primary And Secondary Endpoints With Significant Proteinuria Reductions

Vera Therapeutics

27/10/2024 24:31

Oct 26 (Reuters) - Vera Therapeutics Inc  VERA.O :
    * VERA THERAPEUTICS ANNOUNCES 96-WEEK EGFR STABILIZATION IN
ORIGIN
PHASE 2B STUDY OF ATACICEPT IN IGAN IN A LATE-BREAKING ORAL
PRESENTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK
2024
    * VERA THERAPEUTICS INC - PIVOTAL ORIGIN 3 TRIAL ON TRACK TO
ANNOUNCE TOPLINE RESULTS IN Q2 2025, WITH PLANNED BLA SUBMISSION
TO U.S. FDA LATER IN YEAR
    * VERA THERAPEUTICS INC - TRIAL MET PRIMARY AND SECONDARY
ENDPOINTS WITH SIGNIFICANT PROTEINURIA REDUCTIONS

Source text:  ID:nGNX94hk9J 
Further company coverage:  VERA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))